The SMART-VERAPAF study investigates the effects of different heart rate-lowering medications in patients with paroxysmal atrial fibrillation (AF). This heart rhythm disorder is associated with a large number of emergency room visits and hospitalizations for cardioversions and ablations. In this study, patients with symptomatic paroxysmal AF are randomized to treatment with heart rate reduction using verapamil or metoprolol, both licensed for this indication. In addition, in a subset of patients, the effect of centrally guided self-care using smartwatch data will be evaluated.
The hypothesis is that both verapamil and guided self-care will lead to better heart rate control and fewer cardioversions and pulmonary vein ablations in patients with paroxysmal AF. This will also result in fewer hospital admissions, outpatient visits, and costs, as well as improved quality of life.
Age ≥ 18 years old
ECG documented diagnosis of paroxysmal AF
Presence of symptomatic paroxysmal AF, defined as recurrent self-terminating AF (≥ 2 episodes in last 4 months) documented by typical symptoms, ECG or photoplethysmo-gram
Able and willing to sign informed consent.
A history of electrical cardioversion for persistent AF
History of AF episode > 7 days
Previous or current chronic amiodaron use.
A history of pulmonary vein ablation
Parallel
Verapamil 240 mg slow-release tablet
Drugrate control with verapamil 240 mg od
metoprolol 100 mg slow-release tablet
DrugRate control with metoprolol 100 mg od
The time to hospitalization for AF, cardioversion, or referral for pulmonary vein ablation
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
